NASDAQ

Decoy Therapeutics Inc. (DCOY)

588 Thanks from members

Decoy Therapeutics Inc. (DCOY) trades as a micro-cap preclinical biotechnology company (~$2M market cap) developing AI-enabled D-MAVs via its IMP3ACT platform. While Wall Street holds a consensus Hold-to-Buy with a $30 target, alternative data, weak fundamentals, and severe historical reverse splits reflect deep value-trap risks.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →